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“Amphotericin B acts through pore formation at the cell membrane after binding to
ergosterol” is an accepted dogma about the action mechanism of this antifungal, and
this sentence is widely found in the literature. But after 60 years of investigation, the
action mechanism of Amphotericin B is not fully elucidated. Amphotericin B is a polyene
substance that is one of the most effective drugs for the treatment of fungal and
parasite infections. As stated above, the first mechanism of action described was pore
formation after binding to the ergosterol present in the membrane. But it has also been
demonstrated that AmB induces oxidative damage in the cells. Moreover, amphotericin B
modulates the immune system, and this activity has been related to the protective effect
of the molecule, but also to its toxicity in the host. This review tries to provide a general
overview of the main aspects of this molecule, and highlight the multiple effects that this
molecule has on both the fungal and host cells.
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INTRODUCTION
The control of invasive fungal infections is based on the use of
antifungal drugs, being polyenes, azoles, and echinocandins the
main families used in clinical practice. Among these, polyenes
are the drugs that have been in use for a longer time, since
they were first described in the middle of the twentieth century
(Oura et al., 1955). The main polyene used as antifungal drug
is Amphotericin B (AmB), which is an amphipatic macrolide.
This molecule was discovered in 1950s after a broad screening
of Streptomycete cultures that contained antifungal activity. The
AmB-producing organism was isolated from a soil sample taken
from the Orinoco River region (Venezuela) and was identified
as Streptomyces nodosus (Trejo and Bennett, 1963). An intra-
venous presentation was introduced in the market in 1958 as
a sodium deoxycholate solution (D-AmB) (Fungizone-Squibb),
which forms a micellar suspension when reconstituted in glucose
solution.
AmB has been used for the treatment of fungal infections
and, despite the toxicity and the development of other antifun-
gals, such as azoles and echinocandins, this drug remains as the
first line treatment for severe and life threatening systemic infec-
tions such as cryptococcal meningitis and invasive zygomycosis
(Saag et al., 2000; Waness et al., 2009). AmB is also effective for
other mycoses such as aspergillosis, candidiasis, histoplasmosis,
blastomycosis, coccidioidomycosis, sporotrichosis, fusariosis, and
phaeohyphomycosis in the cases of lack of response to azoles
or echinocandins. (Ellis, 2002; Davis and Porter, 2005; Metcalf
and Dockrell, 2007; Chandrasekar, 2008; Gomez-Lopez et al.,
2008; Muhammed et al., 2011). Additionally, AmB has activity
against parasites as Trypanosoma cruzi, Schistosoma mansoni,
Echinococcus multilocularis, and Leishmania spp, being the sec-
ond drug of choice for the treatment for visceral leishmaniasis
when antimonials fail or cannot be used (Yardley and Croft, 1999;
Reuter et al., 2003; Mone et al., 2010; Paila et al., 2010). Also
an amphotericin-derived drug, MS8209, has effect against HIV-1
infection avoiding virus entry to the cell (Pleskoff et al., 1995).
The D-AmB formulation has been considered the gold
standard for many years and it has broad-spectrum activity.
Unfortunately, this formulation is highly nephrotoxic and shows
side effects as fevers, malaise, weight loss, headache, hypotension,
abdominal pain, nausea, vomiting, diarrhea, normochromic nor-
mocytic anemia, and myalgia (Sabra and Branch, 1990; Meunier
et al., 1991; Ringden et al., 1991; Gulati et al., 1998; Laniado-
Laborin and Cabrales-Vargas, 2009). For this reason, new formu-
lations have been introduced in the last years (Lopez-Berestein
et al., 1985; Bohme and Hoelzer, 1996; Gulati et al., 1998; Rust
and Jameson, 1998; Walsh et al., 1998; Dupont, 2002). The
new presentations have reduced toxicity because they are lipid-
carried presentations. These last formulations include a colloidal
dispersion with cholesterol sulphate (CD-AmB, Amphotec), a
lipidic complex with two phospholipids (LC-AmB, Abelcet) and
liposomal AmB (L-AmB, Ambisome), which is integrated into
true unilamellar liposomes (Veerareddy and Vobalaboina, 2004;
Torrado et al., 2008). These different formulations differ in their
price and in the associated toxicity. Lipid-based formulations, and
in particular, L-AmB, have reduced nephrotoxicity and have supe-
rior efficacy than conventional AmB (Gulati et al., 1998; Saliba
and Dupont, 2008).
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MECHANISM OF ACTION OF AMPHOTERICIN B
The mechanism of action of AmB still is not completely elu-
cidated. AmB has effects on the fungal cell at two different
levels: Binding to the ergosterol at the membrane, inducing pore
formation and ergosterol sequestration, and induction of oxida-
tive damage. In the following sections we will summarize how
AmB exerts these two effects on the fungal cells, which are also
summarized in Figure 1.
EFFECTS ON THE FUNGAL MEMBRANE: PORE FORMATION AND
ERGOSTEROL SEQUESTRATION
Early studies suggested that AmB inserts into the fungal lipid
bilayer through the hydrophobic domains that bind to ergos-
terol. As a consequence, multimeric pores are formed, with the
lipophilic polyene chains of the antifungal in contact with mem-
brane lipids (Finkelstein and Holz, 1973; Brajtburg et al., 1990).
AmB pores increase the permeability of the fungal membrane to
small cations as K+, Ca2+, and Mg2+ promoting the rapid deple-
tion of intracellular ions and fungal cell death (Kinsky, 1970).
AmB can also bind to other sterols, such as cholesterol, but with a
lower affinity (Hsuchen and Feingold, 1973).
Recently, it was proposed that AmB can exert its action
through two complementary mechanisms depending on the
interaction of AmB and sterols: membrane permeabilization and
sterol sequestration (Palacios et al., 2011). In this sense, it has been
proposed that cholesterol sequestration in the host membrane
avoids macrophage–parasite interaction in Leishmania infec-
tion as a novel mechanism for AmB in visceral leishmaniasis
(Chattopadhyay and Jafurulla, 2011).
Analytical studies have demonstrated that AmB forms two dif-
ferent types of pores, which differ in their substrate specificities
and that are formed at different moments. Moreover, they par-
ticipate differentially in the killing effect of the molecule [see
seminal review in Cohen (2010) andHartsel et al. (1994); Romero
et al. (2009)]. After addition of AmB to the cells, the first type
of pores that are formed are non-aqueous, which are permeable
to monovalent cations and have lower permeability to monova-
lent anions (Ramos et al., 1996; Romero et al., 2009). Afterwards,
FIGURE 1 | Amphotericin B action mechanisms on fungal cells.
Amphotericin B exerts its action at different levels on the cell: membrane
effects and intracellular effects. At the membrane, it can bind to ergosterol
(1) and form pores, or merely induce ergosterol sequestration (2) resulting in
membrane stability disruption. In the cell, AmB also induces an oxidative
burst. The mechanism of this induction remains unknown, but there are
several possibilities: AmB can act directly as a prooxidant (3) and induce
accumulation of reactive oxygen species (ROS). However, it is also possible
that this intracellular effect requires previous binding to ergosterol (4). Since
ROS are natural products of the respiratory chain, it cannot be discarded that
AmB influences the mitochondrial activity (5), and contribute in this way to
the oxidative burst. The accumulation of free radicals has multiple deleterious
effects on the essential components of the cell (membrane, proteins, DNA
and mitochondria) resulting in cell death.
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aqueous-pores are formed, which are permeable to monovalent
cations and anions and large electrolytes, such as glucose (Cohen
and Gamargo, 1987; Ramos et al., 1989; Cohen et al., 1990;
Cohen, 1992). The formation of pores is a very rapid process, and
occurs in milliseconds. Furthermore, although AmB has affinities
for both ergosterol and cholesterol (Hsuchen and Feingold, 1973),
pore formation is delayed in liposomes formed with cholesterol
(Mouri et al., 2008). The ergosterol and cholesterol content also
determines the concentration at which AmB forms aqueous or
non-aqueous pores, indicating that membrane composition has a
profound effect on the AmB action (Mouri et al., 2008).
Ergosterol is required for multiple processes, such as endo-
cytosis, vacuole fusion, and stabilization of proteins at the cell
membrane (Heese-Peck et al., 2002; Zhang et al., 2010). So bind-
ing of AmB to these molecules could account for the toxic effect
of the antifungal by a mechanism that involves ergosterol seques-
tration. This idea is supported by a recent work (Gray et al.,
2012) that demonstrated that channel formation by AmB is a sec-
ondary mechanism that enhances the activity of the drug, but
is not required to induce killing in the fungal cells. Using dif-
ferent forms of AmB that had been chemically modified, it was
found that modifications that affect pore formation do not affect
its antifungal activity. In this sense, it has been shown that other
polyenes, such as natamycin, have antifungal effects that are not
related to pore formation (Te Welscher et al., 2010).
INDUCTION OF OXIDATIVE DAMAGE
Although it is well established that AmB binds to sterols and
forms pores, there are numerous articles that indicate that
increased permeability might not be the only mechanism respon-
sible for the killing effect of the molecule. Early studies found that
there was not correlation between the lethal effect of different
polyenes on C. albicans and the degree of potassium release by
the cells, suggesting that pore formation does not correlate with
killing of the cells (Chen et al., 1978; Sokol-Anderson et al., 1986).
This finding indicates that the formation of non-aqueous (cation-
selective) pores is not enough to induce killing of the cells, and
suggests that AmB elicits other killing mechanism. In this sense,
it has been observed that the biological effect of AmB is very
complex and depends on a variety of factors, such as the growth
phase of fungi (Gale, 1974; Gale et al., 1975; Mowat et al., 2008)
and the presence of oxygen (Gale et al., 1977; Sokol-Anderson
et al., 1986). These data suggest that AmB action depends on
metabolic factors, and indicate that the action mechanism is more
complex that binding to ergosterol and pore formation. In fact,
some studies argue against the idea that pore formation is the
main killing mechanism. Chemical modifications of the AmB
molecule that interfere with its ability to form pores do not affect
its fungicidal activity (Palacios et al., 2007), which provides strong
evidence that pore formation is not essential for the function of
the molecule.
In agreementwith the idea thatAmBhasother toxicmechanism
than pore formation at the membrane, it has been shown that this
antifungal induces oxidative stress in the cells (Sokol-Anderson
et al., 1986; Haido and Barreto-Bergter, 1989; Sangalli-Leite et al.,
2011). An early study demonstrated that addition of free rad-
icals scavengers, such as catalase and/or superoxide dismutase,
protects C. albicans protoplasts from the lytic effect of AmB
(Sokol-Anderson et al., 1986). Genome-wide expression analysis
confirmed that AmB, not only has an effect on the expression of
genes involved in ergosterol synthesis pathway, but also induces
the expression of stress genes (Liu et al., 2005), providing another
evidence that AmB has pleiotropic effects in the fungal cells.
The induction of oxidative damage in the cells has been fre-
quently reported in the literature using independent approaches.
The direct production of free radicals by AmB has been measured
using probes that emit fluorescence after being attacked by the
free radicals, such as dihydrofluorescein diacetate or dihydrorho-
damine 123 (Phillips et al., 2003; Sangalli-Leite et al., 2011). Lipid
peroxidation, protein carbonylation, and apoptotic-like pheno-
types (such as DNA fragmentation and anexin V staining) have
been also used as indicators of oxidative stress generated by AmB
in fungal cells (Phillips et al., 2003; Mousavi and Robson, 2004;
Blum et al., 2008; Al-Dhaheri and Douglas, 2010; Sharma et al.,
2010; Sangalli-Leite et al., 2011).
The role of oxidative damage in the antifungal effect of AmB is
still unknown, but different studies suggest that this mechanism
participates in this effect. A recent study demonstrates that killing
of C. neoformans cells, measured by propidium iodide uptake,
occurs after the induction of an oxidative burst. The mecha-
nism by which AmB induces oxidative burst in the cells remains
unknown. Several studies demonstrate that AmB can autooxidize,
which suggests a mechanism by which AmB induces oxidative
stress in the cells (Lamy-Freund et al., 1985; Sokol-Anderson
et al., 1986). On the other hand, it has been demonstrated that
AmB can also act as an antioxidant similar to carotenoid and
retinoids (Osaka et al., 1997).
AmB induces oxidative damage in organisms others than fungi
(Haido and Barreto-Bergter, 1989). Moreover, this feature of the
antifungal has been related to the reduction in virulence observed
in some parasite infection models. For example, AmB does not
have a direct effect on development of the miracidia (larval
stages) and sporocyst of the parasite Schistosoma mansoni, but it
decreases its infectivity through a process linked to the oxidative
damage induced by the antifungal that impaired the response of
the parasite during infection (Mone et al., 2010).
MECHANISMS OF RESISTANCE TO AmB
Acquired resistance to AmB is very low despite its widespread use.
Secondary resistance has been described in C. tropicalis, C. parap-
silosis, C. lusitanie, and C. haemulonii (Powderly et al., 1988; Ellis,
2002). In contrast, in the last years, there has been an increase in
the incidence of infections caused by fungi intrinsically resistant
to AmB, such asA. terreus, Fusarium spp, and Scedosporium prolif-
icans (Cuenca-Estrella et al., 1999; Sutton et al., 1999; Khan et al.,
2007; Rogasi et al., 2007).
Resistance to this antifungal is achieved in different ways.
Decrease in ergosterol content results in resistance to this com-
pound (Kim and Kwon-Chung, 1974; Kim et al., 1974; Woods
et al., 1974; Safe et al., 1977; Drutz and Lehrer, 1978; Merz and
Sandford, 1979; Kreiner et al., 1993; Kelly et al., 1994; Currie et al.,
1995; Ghannoum and Rice, 1999; Walsh et al., 2003; Vandeputte
et al., 2007). Most of these studies showed alterations in the ergos-
terol synthesis pathway and accumulation of sterol intermediates.
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Moreover, in biofilms (which are microbial populations that grow
attached to a surface and have reduced susceptibility to antimi-
crobials), resistance to AmB has been associated not only to a
decrease in the ergosterol content, but also to changes in the cell
wall (Khot et al., 2006). Since azoles inhibit ergosterol synthesis,
cross resistance between azole and AmB has been described in the
literature (Sud and Feingold, 1983; Kelly et al., 1996, 1997; Nolte
et al., 1997; Sanglard et al., 2003).
However, other studies did not find a correlation between
ergosterol content and susceptibility to AmB (Joseph-Horne et al.,
1996a,b; Dannaoui et al., 2000). In agreement, it has been shown
that pre-exposure of C. albicans cells to fluconazole can protect
the yeasts from AmB treatment, and this effect is still present
when ergosterol is added to the medium, suggesting that this
resistance phenotype does not depend on ergosterol (Vazquez
et al., 1998). Interestingly, it has been recently shown that subin-
hibitory concentrations of fluconazole induce a response in yeast
that confer resistance to oxidative and nitrosative stress (Arana
et al., 2010), which supports the idea that adaptation to oxidative
stress can result in AmB tolerance. Resistance to AmB has been
also studied using genome-wide expression analysis in C. albicans
(Barker et al., 2004). This work demonstrated that resistance to
AmB and fluconazole was associated, not only with an increase in
the expression or ERG genes, but also with the induction of stress
genes such as catalase, and reduction of mitochondrial enzymes,
such as cytochrome c oxidase and acetyl CoA synthetase, suggest-
ing that resistance to AmB could be associated to a decrease in
mitochondrial activity and reactive oxygen intermediates (ROIs)
production.
A strong support for the role of oxidative damage in the anti-
fungal activity of the drug is provided by the relationship between
resistance to AmB and to oxidant stress. This was first described
in C. albicans, where it was observed that resistant strains to
AmB had reduced susceptibility to H202 (Sokol-Anderson et al.,
1988). In this work, resistance to AmB and H2O2 correlated with
increased catalase activity. Another evidence of the importance
of the oxidative damage was provided in the filamentous fungi
Aspergillus terreus, which is considered intrinsically resistant to
AmB. This fungus has similar ergosterol levels than a susceptible
species, such as A. fumigatus (Dannaoui et al., 2000; Blum et al.,
2008). However, AmB did not induce lipid peroxidation in A. ter-
reus, suggesting that this fungus has an induction in antioxidant
mechanisms. In agreement, catalase activity in A. terreus was sig-
nificantly higher in this fungus than in A. fumigatus (Blum et al.,
2008).
The respiratory chain in the mitochondria plays a key role in
the production of free radicals in the cells because these molecules
are subproducts of the respiration. So it is tempting to correlate
the effect of AmB with the mitochondrial activity. Little is known
about this correlation, but it has been demonstrated that disrup-
tion of respiratory function results in increased resistance to AmB
inC. albicans (Geraghty and Kavanagh, 2003). This finding is very
relevant, especially because the mitochondria is not only required
for the accumulation of free radicals, but also because it is nec-
essary for ergosterol biosynthesis, so changes in mitochondrial
activity can influence the antifungal activity of AmB at multiple
levels.
AmB AS A MOLECULEWITH IMMUNOMODULATORY
PROPERTIES
Antifungal drugs are derived from natural compounds with com-
plex structure, and many of them have other effects than growth
inhibition or killing of fungi. In this sense, antifungals have
inmmunomodulatory properties [see review in Ben-Ami et al.
(2008)]. AmB is a good example about this type of drugs. Besides
the direct action on the fungal cell, several studies have shown
that AmB has a potent immunomodulatory effect on the host
cells. This has been demonstrated in vitro in different cellular lines
from human and murine models, such as polymorphonuclear
neutrophils (PMNs), macrophages, NK cells, T, B, and tumoral
cells, but also in vivo in animal models. The immunomodulatory
properties offer an alternative action mechanism for this antifun-
gal by enhancing the immune response of the host. But at the
same time, this effect has been related to toxicity associated to this
drug. In the following sections, we will briefly review the main
immunomodulatory properties of AmB.
IMMUNOMODULATION IN VITRO AND IN VIVO
Multiple studies performed in vitro and in vivo have demonstrated
that AmB has an effect on the host, not only in the presence
of the pathogen, but also when uninfected cell lines or animals
are treated with the antifungal. AmB stimulates transcription and
production of multiple mediators of the immune system (such
as cytokines, chemokines, and prostaglandins) and ICAM-1 in
murine and human cells (Borden and Leonhardt, 1976; Sculier
and Body, 1991; Cleary et al., 1992; Louie et al., 1994; Saxena et al.,
1999; Rogers et al., 2000; Sau et al., 2003; Camacho et al., 2004;
Simitsopoulou and Roilides, 2005; Simitsopoulou et al., 2005).
Moreover, this antifungal upregulates the expression of genes
involved in angiogenesis (Lin et al., 2009). AmB also induces the
accumulation of nitric oxide (NO) (Mozaffarian et al., 1997) and
ROIs (Wilson et al., 1991). Most of these effects are summarize
in Figure 2. In endothelial activated cells, AmB increases iNOS
expression mediated by endogenous IL-1 and, in consequence,
AmB augments the production of NO, which plays important role
in vasodilation and protection against pathogens (Suschek et al.,
2002).
The immunomodulatory properties and the proinflamma-
tory effect induced by AmB have been associated with protective
effects during infection. AmB enhances the antifungal activity
of PMN and pulmonary alveolar macrophages against conidia
and/or hyphal phase ofA. fumigatus (Roilides et al., 2002). Similar
results were published with murine peritoneal macrophages pre-
treated with IFN-γ and different doses of AmB. In this case
AmB induced the production of NO, TNF-α, and IL-1, that
enhanced the anticryptococcal activity of these cells (Tohyama
et al., 1996).
Macrophage oxidative burst, leading to O−2 release, is activated
in vivo after intraperitoneal injections of recombinant IFN-γ and
TNF-α or AmB (Wolf and Massof, 1990). Moreover, when AmB
was combined with IFN-γ, a synergic effect was observed, sug-
gesting that IFN-γ may serve as a useful adjuvant during the
treatment of intracellular fungal infections.
AmB also produces oxidative burst in macrophages follow-
ing stimulation with phorbol myristate acetate. This effect was
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FIGURE 2 | Immunomodulatory effects of AmB. Different formulations
of AmB can bind to Toll-like receptors (TLR-2 or TLR-4) or CD14, resulting
in immunomodulation of the cell. The signal is transduced through the
adaptor protein MyD88, and as a final effect, NF-kB is activated and
translocated to the nucleus. In this way, cytokines are expressed,
which can be pro- or anti-inflammatory, depending on the AmB formulation,
and receptors involved (see text for further details). AmB also induce the
accumulation of free radicals (reactive oxygen intermediates, ROIs, and
nitric oxide, NO) through induction of NO synthase and NADPH
oxidase
related to the binding to the antifungal to the membrane that
could in turn induce conformational changes that activate mem-
brane enzymes involved in the induction of oxidative burst,
such as NADPH oxidase (Chapman and Hibbs, 1978; Wilson
et al., 1991). AmB also has a cooperative effect with IFN-γ in
enhancing the candidastatic activity of the macrophages through
a process that involves the accumulation of ROIs (Coste et al.,
2002). However, the same authors also noticed that AmB had
a cooperative effect with IL-13, but this effect was indepen-
dent of ROIs, indicating that AmB can activate macrophages in
different ways.
The outcome of systemic and mucosal fungal infections
depends on the Th response of the host. Th1 response (which
depends on proinflamamatory cytokines TNF-α, IFN-γ, IL-1,
IL-6) leads to resistance because it primes the immune system
with macrophage inflammatory activation and superoxide and
NO production. In contrast, a Th2 response (IL-10, IL-4, IL-2,
IL-13, and IL-5) is associated with susceptibility to infection and
disease enhancement (Puccetti et al., 1995; Romani and Howard,
1995). To evaluate the effect of AmB on the Th cell response, mice
with disseminated or gastrointestinal candidiasis were treated
with antifungal alone or in combination with an IL-4 antagonist,
and the production of IFN-γ (Th1) and IL-4 (Th2) was evalu-
ated. AmB induced a protective Th1 response with concomitant
IL-4 depletion (Cenci et al., 1997). Similar results were observed
in Balb/c mice infected with A. fumigatus spores and treated with
AmB (Saxena et al., 1999). In agreement, it was described that
AmB induces up-regulation of IL-1β and TNF-α in mouse kid-
ney (Falk et al., 2005). The idea that AmB exerts part of its
effect through immunomodulation was supported by the fact the
antifungal shows a defect in the protection when mice receive
neutralizing TNF-α antibodies (Louie et al., 1995).
Since changes in the immune response could have profound
consequences in the host, the immunomodulatory properties of
AmB can explain some of the secondary effects of the molecule.
For example, the increase in proinflammatory cytokines has been
correlated with the toxicity of AmB (Chia and McManus, 1990;
Cleary et al., 1992; Arning et al., 1995; Shadkchan et al., 2004). In
addition, direct renal toxicity has been described by the induction
of apoptosis and alterations in the expression of the constitutive
NO synthase (Suschek et al., 2000; Falk et al., 2005; Yano et al.,
2009).
AmB has been occasionally described to have immunosupres-
sor effects. In the human THP-1monocytic cell line, pretreatment
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with AmB and challenge with A. fumigatus conidia results in
reduced expression of TNF-α (Choi et al., 2010). Also Becker
et al. observed decrease of IL-6, macrophage inflammatory pro-
tein (MIP-2), and monocyte chemoattractant protein (MCP-1)
in neutropenic rats with invasive pulmonary aspergillosis treated
with AmB (Becker et al., 2003).
MECHANISMS BY WHICH AmB INDUCES IMMUNOMODULATION
The mechanism by which AmB produces immunomodulation
and induction of ROIs and NO is not fully elucidated. As stated
above, AmB binds to the mammalian membrane because it
presents affinity to cholesterol, and in this way, it could induce
conformational changes that activate the NADPHoxidase enzyme
(Chapman and Hibbs, 1978; Wilson et al., 1991) (Figure 2).
But the mechanism that better explains the immunomodula-
tory effects of AmB is mediated through the Toll-like receptor
(TLRs) signaling pathway (Figure 2). TLRs are members of a
conserved family of mammalian receptors that recognize micro-
bial products, being TLR2 and TLR4 the best characterized.
TLR2 presents affinity for Gram-positive bacteria, peptidoglycan,
lipoteichoic acid, and zymosan, whereas TLR4 ligands include
LPS from Gram-negative bacteria, Taxol, and Cryptococcus neo-
formans capsular polysaccharide (Shoham et al., 2001; Janeway
et al., 2005). AmB can bind to TLR, resulting in cytokine and
chemokine release. Binding to TLR2 has been associated to
release of proinflammatory cytokines, while binding to TLR4
produced release of anti-inflammatory (Bellocchio et al., 2005).
Binding of AmB to the TLRs triggers polymerization of receptors
which results in recruitment of the adaptor protein, MyD88. This
signaling produces the nuclear translocation of NF-kB, which
induces the expression of genes involved in macrophage acti-
vation. In addition, AmB also exerts its immunomodulatory
effect through CD14 (Trajkovic et al., 2001; Sau et al., 2003),
which is a receptor that activates the TLR signaling pathway after
binding to LPS.
EFFECT OF THE AmB FORMULATIONS ON THE
IMMUNOMODULATORY PROPERTIES
The immunomodulatory properties of AmB depend on the
clinical presentation used in the treatment. In a study using
plasma of patients treated with different presentations, it was
found that D-AmB and L-AmB increased TNF-α, IL-6, and
IL-1-RA, but this effect was not observed when patients were
treated with CD-AmB (Arning et al., 1995). In humanmonocytes
D-AmB and CD-AmB induced up-regulation of inflammatory
cytokines such as IL-1, TNF-α, monocyte chemotactic protein
1 (MCP-1), and macrophage inflammatory protein 1 (MIP-
1), while LC-AmB lipid complex and L-AmB down-regulated
or had no effect on the gene expression of these proin-
flammatory cytokines (Simitsopoulou et al., 2005). Moreover,
D-AmB is more effective than LC-AmB in enhancing PMN
oxidative activity and D-AmB induced higher expression of
CD11b/CD18 integrin (Mac-1) (Sullivan et al., 1992). On the
other hand, using antibody arrays, both D-AmB and CD-
AmB induced proinflammatory cytokines in the THP-1 mono-
cytic cell line (IL-8, TNF-γ, MCP-1, and RANTES) while
LC-AmB and L-AmB had no effect (Turtinen et al., 2004).
This difference between the AmB formulations can be explained
by the type of TLR to which the different AmB presenta-
tions bind. D-AmB binds to TLR2, which induces a pro-
inflammatory response, in contrast to L-AmBwhich induces anti-
inflammatory effect after binding to TLR4 in PMNs (Bellocchio
et al., 2005).
CONCLUSIONS AND FUTURE PERSPECTIVES
AmB is still an enigmatic molecule, and although it has been
vastly used for the treatment of fungal infections during decades,
there are still aspects about its action mechanism that remain
unknown. Although the first studies demonstrated that this drug
binds to sterols and in particular, ergosterol, and forms pores at
the membrane, it has been also shown that AmB induces oxida-
tive damage in the cells. There are contradictory data about the
importance of these mechanisms. The fact that resistance to this
antifungal correlates with different mechanisms, such as a reduc-
tion in ergosterol content or induction of antioxidant enzymes
indicates that most probably both are required for the killing
effect of the molecule. At the moment, it is not possible to know
if these mechanisms are related or are independent, although a
tempting hypothesis is that binding to ergosterol is necessary not
only for pore formation, but also for the induction of oxidative
damage. Further studies are required to clarify the importance of
each mechanism. In addition, the induction of different killing
mechanisms is in agreement with the fact that AmB is the anti-
fungal drug with a stronger fungicidal activity. To make the
situation more complex, AmB has also strong immunomodu-
latory properties, and in particular, it induces proinflammatory
responses. This effect has been associated with protective effects,
but also with the toxicity. The immunomodulatory properties of
the antifungal open many questions about how AmB acts dur-
ing infection, not only on the pathogen, but also on the host.
This issue is of particular interest because patients affected by
fungal infections are immunocompromised. So it is important
to consider that AmB may have different effects on patients with
different immunological states and therefore, the antifungal treat-
ment could have unpredicted consequences in the outcome of the
disease. Although AmB is one of the most effective treatments
for fungal infections and secondary clinical resistance remains
low, there is an increase in the incidence of pathogens that
have intrinsic resistance to this antifungal, such as Trichosporon
spp, A. terreus and Scedosporium prolificans, so more studies
are required to understand the basis of intrinsic resistance and
to provide an efficient strategy for the management of these
infections.
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